Navigation Links
Micell Technologies Presents Data on Novel Drug-Eluting Stents

RALEIGH, N.C., April 18, 2007 /PRNewswire/ -- Micell Technologies announced today that the Company will be presenting data on use of its supercritical fluid (SCF) surface modification technology for drug-eluting stents at the upcoming Society for Biomaterials 2007 Annual Meeting, April 19-21 2007 in Chicago, Illinois.

The abstracts describe use of Micell and PNNL's, 2006 R&D 100 Award winning e-RESS technology to create drug-eluting stents containing crystalline drugs, such as sirolimus, and multiple drug combinations such as paclitaxel and heparin.

e-RESS (e for electrostatic, RESS for Rapid Expansion from Supercritical Solution) is a new technology for creating novel drug-eluting materials for cardiovascular stents and other medical devices. The technology was jointly developed by Micell and scientists at Pacific Northwest National Laboratory (PNNL), and has been licensed exclusively to Micell.

This unique technology has the potential to provide improvements to conventional solvent based systems by maintaining control of drug morphology, targeting drug placement within the coating and customizing elution rates of single or multiple drugs. In addition, the SCF method avoids solvents and high temperatures so it can be used with new therapeutic classes, such as proteins or genes, in addition to existing therapeutic agents.

Link to abstract 1: (http://www.micell.com/development1.pdf)

Link to abstract 2: (http://www.micell.com/development2.pdf)

While drug-eluting stents have demonstrated dramatic improvements in early restenosis rates compared to bare metal stents, concerns over late stent thrombosis have been the subject of much recent discussion in the medical community and the media. These concerns have been driven largely by a number of issues including inherently thrombogenic polymers, residual drugs and patient compliance issues related to the necessary oral anti-platelet therapy such as Plavix and aspirin, required of patients who receive drug-eluting stents.

"Our technology provides an opportunity for optimal design of therapeutic profiles using both anti-restenosis and anti-thrombotic compounds to address both short and long-term safety of drug-eluting stents," said James B. McClain, founder and Chief Technology Officer of Micell Technologies. "This approach which includes multi-drug formulations in biodegradable polymers has the potential to provide improved benefits for both patients and clinicians."

Micell Technologies' novel approach to surface modification of medical devices provides an opportunity to deliver the next generation of drug-eluting stents by maintaining morphology of therapeutic compounds and providing manufacturing processes that apply discrete and independent therapies within a single, multi-therapy coating.

About Micell

Micell Technologies is a privately-held, early-stage biomedical company dedicated to applying its unique surface and polymer modification technologies for improved patient benefits and accelerated product development for medical device and drug delivery applications. The Company's patented processes and methods for medical device surface modification using supercritical fluids are focused on improvements to current polymer based drug-eluting technologies. To learn more, please visit our website at www.micell.com

Contact: James McClain Ph.D., Chief Technology Officer

Micell Technologies: (919) 313-2111

CONTACT: James McClain Ph.D., Chief Technology Officer of MicellTechnologies, +1-919-313-2111

Web site: http://www.micell.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
Breaking Medicine News(10 mins):